XFOR X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an ora…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. | ||
 X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. | ||
 X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | ||
 X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||